Patient, disease, and treatment characteristics
Variables . | Chemotherapy, no. (%) . | Transplant, no. (%) . | P . |
|---|---|---|---|
| No. of patients | 188 | 186 | — |
| Age at diagnosis | <.001 | ||
| Younger than 1 y | 15 (8) | 2 (1) | |
| 1-10 y | 126 (67) | 112 (60) | |
| 11-18 y | 47 (25) | 72 (39) | |
| Male sex | 109 (58) | 126 (68) | .05 |
| WBC count at diagnosis | .60 | ||
| 50 000 × 109/L or less | 104 (55) | 142 (76) | |
| 50 000-100 000 × 109/L | 13 (7) | 12 (7) | |
| Greater than 100 000 × 109/L | 15 (8) | 17 (9) | |
| Unknown | 56 (30) | 15 (8) | |
| Relapse, site | .01 | ||
| Bone marrow (isolated) | 152 (81) | 130 (70) | |
| Bone marrow + other sites | 36 (19) | 56 (30) | |
| Time to first relapse | .84 | ||
| Fewer than 36 mo | 110 (59) | 111 (60) | |
| 36 mo or greater | 78 (41) | 75 (40) | |
| Conditioning regimen | NA | ||
| Cy + TBI ± other | NA | 119 (64) | |
| TBI ± other | NA | 34 (18) | |
| Bu + Cy ± other | NA | 33 (18) | |
| GVHD prophylaxis | NA | ||
| CsA ± other | NA | 45 (24) | |
| MTX ± other | NA | 10 (5) | |
| CsA + MTX ± other | NA | 131 (71) | |
| Donor-recipient sex match | NA | ||
| Female donor→male recipient | NA | 60 (32) | |
| Other | NA | 126 (68) | |
| Donor-recipient CMV status | NA | ||
| Donor (-)/recipient (-) | NA | 79 (42) | |
| Donor (+)/recipient (+) | NA | 49 (26) | |
| Donor (-)/recipient (+) | NA | 29 (16) | |
| Donor (+)/recipient (-) | NA | 24 (13) | |
| Not tested | NA | 5 (3) |
Variables . | Chemotherapy, no. (%) . | Transplant, no. (%) . | P . |
|---|---|---|---|
| No. of patients | 188 | 186 | — |
| Age at diagnosis | <.001 | ||
| Younger than 1 y | 15 (8) | 2 (1) | |
| 1-10 y | 126 (67) | 112 (60) | |
| 11-18 y | 47 (25) | 72 (39) | |
| Male sex | 109 (58) | 126 (68) | .05 |
| WBC count at diagnosis | .60 | ||
| 50 000 × 109/L or less | 104 (55) | 142 (76) | |
| 50 000-100 000 × 109/L | 13 (7) | 12 (7) | |
| Greater than 100 000 × 109/L | 15 (8) | 17 (9) | |
| Unknown | 56 (30) | 15 (8) | |
| Relapse, site | .01 | ||
| Bone marrow (isolated) | 152 (81) | 130 (70) | |
| Bone marrow + other sites | 36 (19) | 56 (30) | |
| Time to first relapse | .84 | ||
| Fewer than 36 mo | 110 (59) | 111 (60) | |
| 36 mo or greater | 78 (41) | 75 (40) | |
| Conditioning regimen | NA | ||
| Cy + TBI ± other | NA | 119 (64) | |
| TBI ± other | NA | 34 (18) | |
| Bu + Cy ± other | NA | 33 (18) | |
| GVHD prophylaxis | NA | ||
| CsA ± other | NA | 45 (24) | |
| MTX ± other | NA | 10 (5) | |
| CsA + MTX ± other | NA | 131 (71) | |
| Donor-recipient sex match | NA | ||
| Female donor→male recipient | NA | 60 (32) | |
| Other | NA | 126 (68) | |
| Donor-recipient CMV status | NA | ||
| Donor (-)/recipient (-) | NA | 79 (42) | |
| Donor (+)/recipient (+) | NA | 49 (26) | |
| Donor (-)/recipient (+) | NA | 29 (16) | |
| Donor (+)/recipient (-) | NA | 24 (13) | |
| Not tested | NA | 5 (3) |
NA indicates not applicable; CY, cyclophosphamide; BU, busulfan; CsA, cyclosporine; MTX, methotrexate.